Literature DB >> 8390762

Activation of protooncogene c-jun by the X protein of hepatitis B virus.

J S Twu1, M Y Lai, D S Chen, W S Robinson.   

Abstract

A specific viral oncogenic mechanism has not been shown for hepatitis B virus (HBV), although persistent HBV infection has been strongly associated with the development of hepatocellular carcinoma (HCC). Most HCCs in HBV carriers contain integrated viral sequences in host DNA and this raises the question of whether such integrations ever contribute to oncogenesis. HBV does contain a gene (designated the hbx gene) which encodes a transcriptional trans-activator protein capable of activating homologous and heterologous regulatory sequences. Hbx has been detected in some human HCC with HBV integrations and the expressed hbx protein appears to have transcriptional transactivating activity. These findings raise the possibility that hbx expression could contribute to hepatocarcinogenesis by activating cellular genes that could contribute to oncogenicity. The possibility that the hbx protein may activate certain protooncogenes was investigated and we found that hbx can activate the protooncogene c-jun promoter. c-Jun was found to be expressed at a very low level in normal liver tissue but at high levels in HCCs of HBV-infected patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8390762     DOI: 10.1006/viro.1993.1041

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  30 in total

1.  Different regions of hepatitis B virus X protein are required for enhancement of bZip-mediated transactivation versus transrepression.

Authors:  S Barnabas; O M Andrisani
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  HBx-DNA probe preparation and its application in study of hepatocarcinogenesis.

Authors:  Feng-Guang Gao; Wen-Sheng Sun; Ying-Lin Cao; Li-Ning Zhang; Jing Song; Hua-Fen Li; Shi-Kun Yan
Journal:  World J Gastroenterol       Date:  1998-08       Impact factor: 5.742

3.  Microinjection technique used to study functional interaction between p53 and hepatitis B virus X gene in apoptosis.

Authors:  X W Wang
Journal:  Mol Biotechnol       Date:  2001-06       Impact factor: 2.695

4.  The hepatitis B virus X gene induces p53-mediated programmed cell death.

Authors:  P Chirillo; S Pagano; G Natoli; P L Puri; V L Burgio; C Balsano; M Levrero
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

5.  The transcription factor c-JUN/AP-1 promotes HBV-related liver tumorigenesis in mice.

Authors:  C Trierweiler; B Hockenjos; K Zatloukal; R Thimme; H E Blum; E F Wagner; P Hasselblatt
Journal:  Cell Death Differ       Date:  2015-10-16       Impact factor: 15.828

Review 6.  Molecular targeted therapy for hepatocellular carcinoma: current and future.

Authors:  Jung Woo Shin; Young-Hwa Chung
Journal:  World J Gastroenterol       Date:  2013-10-07       Impact factor: 5.742

7.  Differential effects on apoptosis induction in hepatocyte lines by stable expression of hepatitis B virus X protein.

Authors:  Nicola Fiedler; Ellen Quant; Ludger Fink; Jianguang Sun; Ralph Schuster; Wolfram H Gerlich; Stephan Schaefer
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

8.  Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls.

Authors:  J Benn; R J Schneider
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

9.  A truncated mutant (residues 58-140) of the hepatitis B virus X protein retains transactivation function.

Authors:  V Kumar; N Jayasuryan; R Kumar
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

10.  Gene expression profile analysis of human hepatocellular carcinoma using SAGE and LongSAGE.

Authors:  Hui Dong; Xijin Ge; Yan Shen; Linlei Chen; Yalin Kong; Hongyi Zhang; Xiaobo Man; Liang Tang; Hong Yuan; Hongyang Wang; Guoping Zhao; Weirong Jin
Journal:  BMC Med Genomics       Date:  2009-01-26       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.